AAOS2018: IV-TXA reduces blood loss, not transfusion rate, in reverse total shoulder arthroplasty
                                                    AAOS2018: IV-TXA reduces blood loss, not transfusion rate, in reverse total shoulder arthroplasty
Intravenous Tranexamic Acid Reduces Blood Loss in Reverse Total Shoulder Arthroplasty: A Prospective, Double-Blinded, Randomized, Controlled Trial
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
102 patients scheduled for reverse total shoulder arthroplasty were randomized to intravenous administration of either tranexamic acid or placebo. Patients were assessed to total blood loss, postoperative blood loss after 24 and 48 hours, hemoglobin drop after 24 and 48 hours, and transfusion requirement. Results demonstrated significantly lower blood loss - total and postoperative - in the IV-TXA...
                To view the full content, login to your account,
or start your 30-day FREE Trial today.
            
            FREE TRIAL
            LOGIN
            Forgot Password?
    Explore some of our unlocked ACE Reports below!
                Learn about our AI Driven 
 High Impact Search Feature
    Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
                    
                
                                                        
                                                        
                                    LOGIN
                                
            
Join the Conversation
Please Login or Join to leave comments.